Welcome to our dedicated page for REGENXBIO news (Ticker: $RGNX), a resource for investors and traders seeking the latest updates and insights on REGENXBIO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REGENXBIO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REGENXBIO's position in the market.
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates. Highest priority programs include ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne, and RGX-121 for MPS II. Restructuring plan includes a 15% reduction in workforce, expected to save at least $100 million. Anticipated cost savings, along with $365 million in cash, expected to fund operational runway into the second half of 2025. Conference call on Wednesday, November 8, 2023, at 4:30 p.m. (EST)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. (RGNX) will participate in two upcoming investor conferences: the Stifel 2023 Healthcare Conference on November 14, 2023, and the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023, both in New York, NY. The fireside chats will be live webcasted and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. announces positive data from Phase II ALTITUDE trial of ABBV-RGX-314 for diabetic retinopathy. Dose level 2 reduced vision-threatening events by 89% compared to control. 70.8% of patients achieved Diabetic Retinopathy Severity Scale improvement. Conference call scheduled for November 6.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
REGENXBIO Inc. will host a conference call on November 8, 2023, at 4:30 p.m. EST to discuss its financial results for the quarter ended September 30, 2023, and recent operational highlights. Listeners can register for the webcast and analysts can participate in the Q&A session. A replay of the webcast will be available on the company's investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.09%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. will present new data for ABBV-RGX-314, an investigational gene therapy, at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. The therapy is being developed for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal conditions. The presentations will include 1-year results for the ALTITUDE® study, which focuses on the suprachoroidal delivery of ABBV-RGX-314 for diabetic retinopathy. The data will be presented by Dr. Mark Barakat and Dr. Arshad Khanani at the conference. REGENXBIO will host a conference call on November 6, 2023, to discuss the results and the ABBV-RGX-314 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. to participate in Jefferies CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
Rhea-AI Summary
RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne, continues to be well-tolerated in three patients from dose level 1. Initial biomarker data in two patients demonstrate robust microdystrophin expression with localization to the muscle cell membrane. Patient aged 4.4 years old had expression level at 38.8% of control. Trial dose escalation expected by end of 2023. Pivotal dose determination and initiation of pivotal program anticipated in 2024. Plan to use RGX-202 microdystrophin as a surrogate endpoint to support a Biologics License Application filing. RGX-202 development program uses commercial-ready cGMP material from the REGENXBIO Manufacturing Innovation Center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. announces presentations at the World Muscle Society Congress, including interim data from the Phase I/II AFFINITY DUCHENNE™ trial. Conference call to review the data will be held on October 3, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. will participate in investor conferences on September 12 and 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
Rhea-AI Summary
RGX-181 trial shows well-tolerated gene therapy with reduced seizure frequency and improved skills
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
REGENXBIO Inc.
Nasdaq:RGNX
RGNX Rankings
RGNX Stock Data
734.90M
37.36M
7.18%
81.62%
8.05%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
ROCKVILLE
About RGNX
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.